|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
DeSantis CE, Ma J, Gaudet MM, Newman LA,
Miller KD, Goding Sauer A, Jemal A and Siegel RL: Breast cancer
statistics, 2019. CA Cancer J Clin. 69:438–451. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harbeck N and Gnant M: Breast cancer.
Lancet. 389:1134–1150. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ebert MS and Sharp PA: Roles for microRNAs
in conferring robustness to biological processes. Cell.
149:515–524. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wozniak M, Mielczarek A and Czyz M: miRNAs
in Melanoma: Tumor suppressors and oncogenes with prognostic
potential. Curr Med Chem. 23:3136–3153. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W,
Yu M, Lin J and Cui Q: MicroRNAs involved in carcinogenesis,
prognosis, therapeutic resistance and applications in human
triple-negative breast cancer. Cells. 8:14922019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu H: MicroRNAs in breast cancer
initiation and progression. Cell Mol Life Sci. 69:3587–3599. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schwarzenbacher D, Klec C, Pasculli B,
Cerk S, Rinner B, Karbiener M, Ivan C, Barbano R, Ling H,
Wulf-Goldenberg A, et al: MiR-1287-5p inhibits triple negative
breast cancer growth by interaction with phosphoinositide 3-kinase
CB, thereby sensitizing cells for PI3Kinase inhibitors. Breast
Cancer Res. 21:202019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ying X, Sun Y and He P: MicroRNA-137
inhibits BMP7 to enhance the epithelial-mesenchymal transition of
breast cancer cells. Oncotarget. 8:18348–18358. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hu W, Wang M, Yin H, Yao C, He Q, Yin L,
Zhang C, Li W, Chang G and Wang S: MicroRNA-1298 is regulated by
DNA methylation and affects vascular smooth muscle cell function by
targeting connexin 43. Cardiovasc Res. 107:534–545. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu X, Ban Y, Zhao Z, Pan Q and Zou J:
MicroRNA-1298-3p inhibits proliferation and invasion of glioma
cells by downregulating Nidogen-1. Aging (Albany NY). 12:7761–7773.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du Z, Wu J, Wang J, Liang Y, Zhang S,
Shang Z and Zuo W: MicroRNA-1298 is downregulated in non-small cell
lung cancer and suppresses tumor progression in tumor cells. Diagn
Pathol. 14:1322019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xue G, Lin X, Wu JF, Pei D, Wang DM, Zhang
J and Zhang WJ: Identification of key genes of papillary thyroid
carcinoma by integrated bioinformatics analysis. Biosci Rep.
40:BSR202015552020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qiu ZK, Liu N, Zhao SF, Ding AP, Cheng G,
Qiu WS and Qi WW: MiR-1298 expression correlates with prognosis and
inhibits cell proliferation and invasion of gastric cancer. Eur Rev
Med Pharmacol Sci. 22:1672–1679. 2018.PubMed/NCBI
|
|
18
|
Chen W, Lu Q, Li S, Zhang X and Xue X:
microRNA-1298 inhibits the malignant behaviors of breast cancer
cells via targeting ADAM9. Biosci Rep. 40:BSR202012152020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Attwooll C, Lazzerini Denchi E and Helin
K: The E2F family: Specific functions and overlapping interests.
EMBO J. 23:4709–4716. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
DeGregori J and Johnson DG: Distinct and
overlapping roles for E2F family members in transcription,
proliferation and apoptosis. Curr Mol Med. 6:739–748. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ginsberg D: E2F1 pathways to apoptosis.
FEBS Lett. 529:122–125. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Helin K, Wu CL, Fattaey AR, Lees JA,
Dynlacht BD, Ngwu C and Harlow E: Heterodimerization of the
transcription factors E2F-1 and DP-1 leads to cooperative
trans-activation. Genes Dev. 7:1850–1861. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Strauss M, Lukas J and Bartek J:
Unrestricted cell cycling and cancer. Nat Med. 1:1245–1246. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu TP, Wang YF, Xiong WL, Ma P, Wang WY,
Chen WM, Huang MD, Xia R, Wang R, Zhang EB, et al: E2F1 induces
TINCR transcriptional activity and accelerates gastric cancer
progression via activation of TINCR/STAU1/CDKN2B signaling axis.
Cell Death Dis. 8:e28372017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang T, Chen X, Qiao W, Kong L, Sun D and
Li Z: Transcription factor E2F1 promotes EMT by regulating ZEB2 in
small cell lung cancer. BMC Cancer. 17:7192017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ren Z, Kang W, Wang L, Sun B, Ma J, Zheng
C, Sun J, Tian Z, Yang X and Xiao W: E2F1 renders prostate cancer
cell resistant to ICAM-1 mediated antitumor immunity by NF-κB
modulation. Mol Cancer. 13:842014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ,
Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA and Kyritsis AP:
Overexpression of E2F-1 in glioma triggers apoptosis and suppresses
tumor growth in vitro and in vivo. Nat Med. 4:685–690. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kent LN, Bae S, Tsai SY, Tang X,
Srivastava A, Koivisto C, Martin CK, Ridolfi E, Miller GC, Zorko
SM, et al: Dosage-dependent copy number gains in E2f1 and E2f3
drive hepatocellular carcinoma. J Clin Invest. 127:830–842. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Frietze S, Lupien M, Silver PA and Brown
M: CARM1 regulates estrogen-stimulated breast cancer growth through
up-regulation of E2F1. Cancer Res. 68:301–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun B, Wingate H, Swisher SG, Keyomarsi K
and Hunt KK: Absence of pRb facilitates E2F1-induced apoptosis in
breast cancer cells. Cell Cycle. 9:1122–1130. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Worku D, Jouhra F, Jiang GW, Patani N,
Newbold RF and Mokbel K: Evidence of a tumour suppressive function
of E2F1 gene in human breast cancer. Anticancer Res. 28:2135–2139.
2008.PubMed/NCBI
|
|
32
|
Lu G, Li Y, Ma Y, Lu J, Chen Y, Jiang Q,
Qin Q, Zhao L, Huang Q, Luo Z, et al: Long noncoding RNA LINC00511
contributes to breast cancer tumourigenesis and stemness by
inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res.
37:2892018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cataldo A, Cheung DG, Balsari A, Tagliabue
E, Coppola V, Iorio MV, Palmieri D and Croce CM: miR-302b enhances
breast cancer cell sensitivity to cisplatin by regulating E2F1 and
the cellular DNA damage response. Oncotarget. 7:786–797. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao YX, Liu HC, Ying WY, Wang CY, Yu YJ,
Sun WJ and Liu JF: microRNA372 inhibits proliferation and induces
apoptosis in human breast cancer cells by directly targeting E2F1.
Mol Med Rep. 16:8069–8075. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Solomon LA, Podder S, He J,
Jackson-Chornenki NL, Gibson K, Ziliotto RG, Rhee J and DeKoter RP:
Coordination of myeloid differentiation with reduced cell cycle
progression by PU.1 induction of MicroRNAs targeting cell cycle
regulators and lipid anabolism. Mol Cell Biol. 37:e00013–17. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Niknami Z, Muhammadnejad A, Ebrahimi A,
Harsani Z and Shirkoohi R: Significance of E-cadherin and Vimentin
as epithelial-mesenchymal transition markers in colorectal
carcinoma prognosis. EXCLI J. 19:917–926. 2020.PubMed/NCBI
|
|
38
|
Das PK, Siddika MA, Asha SY, Aktar S,
Rakib MA, Khanam JA, Pillai S and Islam F: MicroRNAs, a promising
target for breast cancer stem cells. Mol Diagn Ther. 24:69–83.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Z, Li TE, Chen M, Pan JJ and Shen KW:
miR-106b-5p contributes to the lung metastasis of breast cancer via
targeting CNN1 and regulating Rho/ROCK1 pathway. Aging.
12:1867–1887. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wen L, Li Y, Jiang Z, Zhang Y, Yang B and
Han F: miR-944 inhibits cell migration and invasion by targeting
MACC1 in colorectal cancer. Oncol Rep. 37:3415–3422. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun X, Cui M, Zhang A, Tong L, Wang K, Li
K, Wang X, Sun Z and Zhang H: MiR-548c impairs migration and
invasion of endometrial and ovarian cancer cells via downregulation
of Twist. J Exp Clin Cancer Res. 35:102016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Li G, Sun L, Mu Z, Liu S, Qu H, Xie Q and
Hu B: MicroRNA-1298-5p inhibits cell proliferation and the
invasiveness of bladder cancer cells via down-regulation of
connexin 43. Biochem Cell Biol. 98:227–237. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Feliciano A, Garcia-Mayea Y, Jubierre L,
Mir C, Hummel M, Castellvi J, Hernández-Losa J, Paciucci R, Sansano
I, Sun Y, et al: miR-99a reveals two novel oncogenic proteins E2F2
and EMR2 and represses stemness in lung cancer. Cell Death Dis.
8:e31412017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhao W, Cui Y, Liu L, Qi X, Liu J, Ma S,
Hu X, Zhang Z, Wang Y, Li H, et al: Splicing factor derived
circular RNA circUHRF1 accelerates oral squamous cell carcinoma
tumorigenesis via feedback loop. Cell Death Differ. 27:919–933.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chen X, Wu Q, Depeille P, Chen P, Thornton
S, Kalirai H, Coupland SE, Roose JP and Bastian BC: RasGRP3
mediates MAPK pathway activation in GNAQ mutant uveal melanoma.
Cancer Cell. 31:685–696.e6. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hua B, Li Y, Yang X, Niu X, Zhao Y and Zhu
X: MicroRNA-361-3p promotes human breast cancer cell viability by
inhibiting the E2F1/P73 signalling pathway. Biomed Pharmacother.
125:1099942020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Stiewe T and Putzer BM: Role of the
p53-homologue p73 in E2F1-induced apoptosis. Nat Genet. 26:464–469.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Peng X, Zhang Y, Gao J and Cai C: MiR-1258
promotes the apoptosis of cervical cancer cells by regulating the
E2F1/P53 signaling pathway. Exp Mol Pathol. 114:1043682020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Z, Liu W, Zhao L, Huang Z, Chen X,
Ma N, Xu J, Zhang W and Zhang Y: Retinoblastoma 1 protects T cell
maturation from premature apoptosis by inhibiting E2F1.
Development. 145:dev1581392018.PubMed/NCBI
|
|
50
|
Udayakumar T, Shareef MM, Diaz DA, Ahmed
MM and Pollack A: The E2F1/Rb and p53/MDM2 pathways in DNA repair
and apoptosis: Understanding the crosstalk to develop novel
strategies for prostate cancer radiotherapy. Semin Radiat Oncol.
20:258–266. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Xia W, Liu Y, Cheng T, Xu T, Dong M and Hu
X: Correction to: Down-regulated lncRNA SBF2-AS1 inhibits
tumorigenesis and progression of breast cancer by sponging
microRNA-143 and repressing RRS1. J Exp Clin Cancer Res. 39:602020.
View Article : Google Scholar : PubMed/NCBI
|
